By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PharmaMar S.A. 

Pol Ind. la Mina Avenida de los Reyes, 1

Colmenar Viejo  Madrid  28770  Spain
Phone: 34-91-8466000 Fax: 34-91-8466001


Company News
PharmaMar S.A. Release: The Phase III Clinical Trial Using PM1183 In Treating Ovarian Cancer (CORAIL) Continues Following The IDMC's Positive Recommendation 2/8/2016 8:53:06 AM
PharmaMar S.A. And Specialised Therapeutics Asia Sign Licensing And Marketing Agreement For APLIDIN (plitidepsin) Covering Several Asian Countries 2/2/2016 7:45:44 AM
PharmaMar S.A. Sets Up Unit In London 9/15/2015 11:56:10 AM
PharmaMar S.A. Announces License Agreement With TTY Biopharm For APLIDIN (plitidepsin) In Hematological Cancers 7/23/2015 7:55:20 AM
PharmaMar S.A. Initiates The Phase III Study CORAIL For The Anticancer Agent PM1183 In Patients With Platinum-Resistant Ovarian Cancer 6/29/2015 6:20:27 AM
Myriad Genetics, Inc. (MYGN) Partners With PharmaMar S.A. for New HRD Test 3/29/2013 8:23:55 AM
Spanish Biotech PharmaMar S.A. Selects Medidata Solutions, Inc. Clinical Cloud to Accelerate Trials for Marine-Based Oncology Drugs 3/18/2013 10:07:36 AM
PharmaMar S.A. Commences Clinical Trial in U.S. with New Antitumor Product, PM060184 2/8/2011 8:14:33 AM
PharmaMar S.A. Initiates a Phase III Registration Trial with Aplidin(R) in Multiple Myeloma Patients 6/9/2010 10:06:36 AM
PharmaMar S.A. Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention 4/22/2010 10:58:40 AM